Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Candidiasis C. Charunee 9/4/50 Candida sp. • albican • non-albican: C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. parapsilosis Candida infection • LOCAL MUCOUS MEMBRANE INFECTIONS • INVASIVE FOCAL INFECTIONS • CANDIDEMIA AND DISSEMINATED CANDIDIASIS Candida sp. • Normal flora in the gastrointestinal and genitourinary tracts of humans. Candida infection • Immune response is an important determinant of the type of infection. – Benign infections: local overgrowth on mucous membranes – More extensive persistent mucous membrane infections: deficiencies in cell-mediated immunity. – Invasive focal infections: after hematogenous spread or when anatomic abnormalities or devices LOCAL MUCOUS MEMBRANE INFECTIONS • Oropharyngeal candidiasis • Esophagitis • Vulvovaginitis • Chronic mucocutaneous candidiasis Oropharyngeal candidiasis • A common local infection. • Host: infants, older adults who wear dentures, patients treated with antibiotics, chemotherapy, or radiation therapy to the head and neck, and cellular immune deficiency states. • Symptoms: cottony feeling, loss of taste, pain on eating and swallowing, asymptomatic Oropharyngeal candidiasis • Signs: Oropharyngeal candidiasis • Diagnosis: Gram stain or KOH preparation on the scrapings. Budding yeasts with or without pseudohyphae. • Rx: – Clotrimazole troche (10 mg troche dissolved five times per day) – Nystatin suspension (400,000 to 600,000 units four times per day) - Nystatin troche (200,000 to 400,000 units four to five times per day), - For 7 to 14 days Esophagitis • AIDS-defining illness • Clinical: odynophagia or pain on swallowing • Dx: endoscopy – Confirmatory biopsy shows the presence of yeasts and pseudohyphae invading mucosal cells, and culture reveals Candida. Esophagitis • Rx: – Fluconazole 200 mg once daily then 100 mg for 14 d – Amphotericin B 0.3-0.7 mkd iv for 14 d Vulvovaginitis • Risk: associated with increased estrogen levels, antibiotics, corticosteroids, diabetes mellitus, HIV infection, intrauterine devices, and diaphragm use • Symptoms: itching and discharge. Dyspareunia, dysuria, and vaginal irritation. • Signs: vulvar erythema and swelling and vaginal erythema and discharge, which is classically white and curd-like but may be watery Vulvovaginitis • Dx: Wet mount or KOH preparation of vaginal secretions • Rx: – clotrimazole 100 mg vg suppo. for 7 d – fluconazole 150 mg oral single dose Chronic mucocutaneous candidiasis • A rare syndrome • Onset in childhood • Some have autosomal recessive polyglandular autoimmune syndrome type I, referred to as the autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED) syndrome • manifested by chronic mucocutaneous candidiasis and endocrine disorders, such as hypoparathyroidism, adrenal insufficiency, and primary hypogonadism Chronic mucocutaneous candidiasis • Clinical: severe, recurrent thrush, onychomycosis, vaginitis, and chronic skin lesions (hyperkeratotic, crusted appearance on the face, scalp, and hands) • Rx: oral fluconazole,itraconazole RISK FACTORS FOR INVASIVE INFECTION • immunosuppressed patients – Hematologic malignancies – Recipients of solid organ or hematopoietic stem cell transplants – Those given chemotherapeutic agents for a variety of different diseases • intensive care patients – – – – – – – – – Trauma and Burn patients, Neonatal units Central venous catheters Total parenteral nutrition Broad-spectrum antibiotics High APACHE II scores Renal failure requiring hemodialysis Abdominal surgical procedures Gastrointestinal tract perforations and anastomotic leaks INVASIVE FOCAL INFECTIONS • • • • • • • • • • Urinary tract infection Endophthalmitis Osteoarticular infections Meningitis Endocarditis Hepatosplenic or chronic disseminated candidiasis Peritonitis and intraabdominal infections Pneumonia Mediastinitis Pericarditis Urinary tract infection • BLADDER INFECTION AND COLONIZATION • KIDNEY INFECTION BLADDER INFECTION AND COLONIZATION • Risk factors: urinary tract drainage devices; prior antibiotic therapy; diabetes; urinary tract pathology and malignancy. • Most patients with candiduria are asymptomatic. • It is difficult to differentiate between colonization and bladder infection. • Infected patients may have dysuria, frequency, and suprapubic discomfort, no symptoms. • Pyuria with a chronic indwelling bladder catheter that it cannot be used to indicate infection. BLADDER INFECTION AND COLONIZATION • Ascending involvement of the kidneys is uncommon but can occur in urinary tract obstruction or renal transplantation. • Candiuria can be seen in systemic infection, it is accompanied by many other signs and symptoms of disseminated infection. BLADDER INFECTION AND COLONIZATION Recommendations: IDSA • Asymptomatic candiduria rarely requires antifungal therapy, if kidney transplantation, neutropenia, low birth-weight neonates, or urinary tract manipulation. • Asymptomatic candiduria may respond to risk factor reduction by removal of bladder catheters or urologic stents, and discontinuation of antibiotics ]. If it is not possible, placement of new devices or intermittent bladder catheterization may be beneficial. • Symptomatic candiduria should always be treated. • Rx: – Fluconazole 200 mg/day 7- 14 days, – Azole-resistant yeast can be treated with intravenous amphotericin B 0.3-0.7 mg/kg per day for 1-7 days KIDNEY INFECTION • Most commonly occurs in patients with disseminated • Acute infection – Bilateral, consisting of multiple microabscesses in the cortex and medulla • Chronic infection – Involve the renal pelvis and medulla with sparing of the cortex, which reflects ascending infection. – The kidney is usually the only organ involved and the infection tends to be unilateral KIDNEY INFECTION • Rx: – Amphotericin B (0.5 to 1.0 mg/kg/day) – Fluconazole (400 mg/day adjusted for renal function). – At least 2 weeks – removal and replacement of all intravenous catheters Endocarditis • Risk: prosthetic heart valves, IVDU, indwelling central venous catheters and prolonged fungemia. • Dx: Duke criteria • Rx: – Amphotericin B 0.7-1 MKD at least 6 weeks. with fluconazole being substituted for amphotericin B as follow-up therapy. – Resection of the valve and any associated abscesses CANDIDEMIA AND DISSEMINATED CANDIDIASIS • Candidiemia: presence of Candida sp. in the blood • Disseminated candidiasis: several viscera are infected PATHOGENESIS • three major routes by which Candida gain access to the bloodstream: – Through the gastrointestinal tract mucosal barrier – Via an intravascular catheter – From a localized focus of infection, such as pyelonephritis CLINICAL MANIFESTATIONS • Vary from minimal fever to a full-blown sepsis syndrome • Clinical clues: – characteristic eye lesions (chorioretinitis, endophthalmitis), – skin lesions, – much less commonly, muscle abscesses. – signs of multiorgan system failure may present: kidneys, heart, liver, spleen, lungs, eyes, and brain CLINICAL MANIFESTATIONS • Skin lesions: – Suddenly as clusters of painless pustules on an erythematous base; occur on any area of the body. – The lesions vary from tiny pustules or nodular; several centimeters in diameter; and appear necrotic in the center. – In severely neutropenic patients, the lesions may be macular rather than pustular. – Dx: by a punch biopsy. CLINICAL MANIFESTATIONS • Skin lesions CLINICAL MANIFESTATIONS • Eye lesions: – Exogenous: following trauma or surgery on the eye – Endogenous: through hematogenous seeding of the retina and choroid as a complication of candidemia. – Primary presenting symptoms: pain and gradual decrease in visual acuity. – The classic findings of chorioretinal involvement: focal, glistening, white, infiltrative, often mound-like lesions on the retina, a vitreal haze is present; sometimes fluffy white balls or "snowballs" in the vitreous CLINICAL MANIFESTATIONS • Eye lesions CLINICAL MANIFESTATIONS • Muscle abcess – soreness in a discrete muscle group. – warm and swollen DIAGNOSIS • Gold standard: candidemia is a positive blood culture • Blood cultures: H/C +ve 50 % of patients who were found to have disseminated candidiasis at autopsy. • Ophthalmologic evaluation: Once H/C+ve, whether or not they have ocular symptoms • Culture and stain of biopsy material Treatment • CATHETER REMOVAL • ANTIFUNGAL AGENTS – Polyenes: Amphotericin B – Azoles: Fluconazole, Itraconazole and Voriconazole. – Echinocandins:Caspofungin DRUG RESISTANCE • C. albicans; resistance is extremely low • C. krusei; intrinsically resistant to fluconazole due to an altered cytochrome P-450 isoenzyme, sometimes demonstrates decreased susceptibility to amphotericin B – susceptible to voriconazole – increased doses of amphotericin B DRUG RESISTANCE • C. glabrata; many are also resistant to the azoles due to changes in drug efflux, Amphotericin B also has delayed killing kinetics against C. glabrata in vitro – using high doses of fluconazole, amphotericin B DRUG RESISTANCE • C. parapsilosis ; – very susceptible to most antifungal agents; – caspofungin minimal inhibitory concentrations are higher than for other Candida species DRUG RESISTANCE • C. lusitaniae – often resistant to amphotericin therapy; – usually susceptible to azoles and echinocandins Treatment • Fluconazole 400 mg or 800 mg of daily • Amphotericin B 0.7 mg/kg per day • Caspofungin is 50 mg/day after a loading dose of 70 mg • Voriconazole is 3 mg/kg twice daily after a loading dose of 6 mg/kg twice daily for one day. • C. glabrata and C. krusei, higher doses of amphotericin B (1 mg/kg daily of standard amphotericin B • Duration of therapy for candidemia : – A minimum of two weeks of therapy after blood cultures become negative